Fig. 4.
Combination therapy leads to long-lasting tumor-specific immunity.
(A) SJL AML mice (▴) that had been cured with combination therapy were challenged 4 months later with live 105 AML cells. Naive SJL mice (▪) were used as control. All SJL AML mice were resistant to the challenge and rejected the AML cells. (B) At 2 months later, the same mice were injected with a different syngeneic tumor (SJL Ly cells). Control naive (▪) and challenged mice (▴) developed lethal lymphoma. The results are representative of 2 independent experiments.
